---
title: "Instil Bio, Inc. (TIL.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/TIL.US.md"
symbol: "TIL.US"
name: "Instil Bio, Inc."
industry: "Biotechnology"
---

# Instil Bio, Inc. (TIL.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [instilbio.com](https://instilbio.com) |

## Company Profile

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell ...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.86 | 173/604 | - | - | - |
| PB | 0.54 | 39/604 | 1.22 | 0.77 | 0.58 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-07T05:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 25% |
| Overweight | 0 | 0% |
| Hold | 3 | 75% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 9.16 |
| Highest Target | 51.00 |
| Lowest Target | 7.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/TIL.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/TIL.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/TIL.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
